Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-24

Study Completion Date

2026-06-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to evaluate the effects of CL25216 on vasomotor symptoms in women during Perimenopause. Enrolled subjects will receive either CL25216 - 250 mg/day or placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized, Double Blind, Placebo Controlled, Clinical Study to Examine the Benefits of an Oral Product in Panelists With Menopausal Symptoms Including Vasomotor Symptoms (VMS).

NCT07033013

Healthy

RECRUITING NA

One Week Clinical Study in Subjects With Menopausal Symptoms

NCT06794021

Healthy Menopause

COMPLETED NA

Randomized Placebo Controlled Clinical Study of an Oral Product in Subjects With Menopausal Symptoms

NCT06787443

Menopausal Symptoms

COMPLETED NA

A Clinical Study Assessing Efficacy of an Herbal Blend on Menopausal Symptoms and Quality of Life

NCT04228757

Menopause

UNKNOWN NA

Impact of Funcional Exercise and Supplementation in Perimenopausal Women's Health

NCT07251296

Perimenopause Aging

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate the effects of CL25216 on vasomotor symptoms in women during perimenopause. A total of 80 female aged between40-55 years will be included in the study. Assessment of inclusion and exclusion criteria will be done based on clinical and laboratory investigations. The eligible subjects will be randomized as per the computer-generated randomization list. The subjects will be assigned to either CL25216 - 250 mg or placebo arms at 1:1ratio. The subjects will be instructed to take one capsule a day after breakfast for 105 days. Apart from primary and secondary outcomes, the study will also record the vital signs and adverse events to evaluate the herbal composition safety and tolerability. The safety assessment of the CL25216 will also include routine laboratory investigations on blood, urine and clinical chemistry at Screening/Randomisation visit and the final visit of the intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vasomotor Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CL25216

250 mg to take one capsule a day after breakfast for 105 days

Group Type EXPERIMENTAL

CL25216

Intervention Type DIETARY_SUPPLEMENT

250mg to take one capsule a day after breakfast for 105 days

Placebo

One capsule a day after breakfast for 105 days

Group Type OTHER

Placebo

Intervention Type DIETARY_SUPPLEMENT

One capsule a day after breakfast for 105 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CL25216

250mg to take one capsule a day after breakfast for 105 days

Intervention Type DIETARY_SUPPLEMENT

Placebo

One capsule a day after breakfast for 105 days

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy overweight women (BMI: 25-29 kg/m2) aged between 40 to 55 years with reports of changes in their menstrual cycle for at least 3 months.
* Participants needed to have a total score of greater than 16 on the Greene Climacteric Scale (GCS), have an intact uterus and ovaries.
* Early Perimenopausal Women according "The Stages of Reproductive Aging Workshop (STRAW) Classification (-2)" irregular periods without skipping menstrual cycles and more than seven days difference in length of consecutive cycles.
* Subjects with serum FSH \>20 U/L on 3-5 days of menstrual cycle.
* Subjects with normal pelvic TVS and breast mammogram.
* Subjects with normal fasting blood glucose level (\<125 mg/dl).
* Subject understands the study procedures and provides signed informed consent to participate in the study.
* Subjects with normal blood thyroid profile.
* Females of childbearing potential who are sexually active must agree to use adequate contraception and can neither be pregnant nor lactating from screening throughout the duration of the study.
* Clinical screening including vital signs, electrocardiogram (ECG) and laboratory evaluations (including clinical chemistry, haematology, and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.

Exclusion Criteria

* History of cerebrovascular disease, thrombo-embolic disorders, heart attack, or angina at any time or thrombophlebitis within the last 5 years, on anti-coagulant or anti-platelet drugs daily for any conditions.
* Subjects who had received hormonal treatment or any other herbal products in the previous 6 months.
* Subjects underwent treatment for COVID 19 within last 3 months or tested positive during the study will be excluded.
* Subjects diagnosed with ovarian cysts ≥ 4 cm or any underlying pathology in pelvic ultrasonography (USG) performed during screening.
* Chronic or acute life stressors relating to a major life change, experiencing depression and/or receiving medication for such illness or disorders, receiving statins or other drugs known to impact on steroid hormone levels.
* Subjects having active gall bladder disease, gynaecological or breast surgery in the last 6 months.
* History of breast, endometrial, other gynaecological cancer at any time or other cancer within the last 5 years.
* Subjects with abnormal ECG.
* Pregnant and breast feeding female.
* History of hypersensitivity reactions attributed to investigational product (IP) or its components or related products.
* Donation/loss of blood 1 unit or 350 mL within 90 days prior to receiving the first dose of study medication.
* Use of any recreational drugs (cocaine, amphetamine, barbiturates, benzodiazepines, cannabinoids, and morphine).
* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol.
* Participated in a clinical study with an investigational drug or biologic within the last 30 days.
* Any condition that in opinion of the investigator, does not justify the subjects" participation in the study.
* Subjects with a high blood pressure at screening (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥ 100 mmHg).
* Subjects with progressive systemic diseases (e.g. tuberculosis, leucosis, collagenosis, multiple sclerosis, AIDS, HIV infections, Hepatitis B surface antigen or Hepatitis C virus (HCV) antibodies or other auto-immune diseases).
* Evidence or history of clinically significant (in the judgment of the Investigator) haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, or malignancies, hypothyroidism.
* High alcohol intake (\>2 standard drinks per day), smokers (\>5 cigarettes per day).

Minimum Eligible Age

40 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes